Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus–Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311
Katherine A. Hutcheson(The University of Texas MD Anderson Cancer Center), Barbara Burtness(Yale University), Yael Flamand(Dana-Farber Cancer Institute), Harry Quon(Johns Hopkins University), Wayne M. Koch(Johns Hopkins University), Nabil F. Saba(Emory University), Francisco Civantos(University of Miami), Jan S. Lewin(The University of Texas MD Anderson Cancer Center), Saral Mehra(Yale University), Ranee Mehra(University of Maryland, Baltimore), Carly E. A. Barbon(The University of Texas MD Anderson Cancer Center), R. Bryan Bell(Takara (United States)), Neil D. Gross(The University of Texas MD Anderson Cancer Center), Tom Thomas(Nuffield Orthopaedic Centre), Beatrice Manduchi(The University of Texas MD Anderson Cancer Center), Robert L. Ferris(University of Pittsburgh), Christine B. Peterson(The University of Texas MD Anderson Cancer Center), Thomas J. Gal(University of Kentucky), Seungwon Kim(Chonnam National University Hospital), Gregory S. Weinstein(University of Pennsylvania), Russel B. Smith(Jackson Memorial Hospital), Enver Özer(The Ohio State University Wexner Medical Center), F. Christopher Holsinger(Stanford University)
Cited by 2
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k